Real-world use and outcomes of belimumab in childhood-onset lupus: A single-center retrospective study

贝里穆马布 医学 单中心 回顾性队列研究 内科学 系统性红斑狼疮 儿科 中心(范畴论) 疾病 B细胞激活因子 免疫学 抗体 结晶学 化学 B细胞
作者
Jordan E. Roberts,Cordelia Burn,Rebecca E. Sadun,Emily A. Smitherman,Scott E. Wenderfer,Mary Beth F. Son
出处
期刊:Lupus [SAGE Publishing]
卷期号:32 (9): 1111-1116 被引量:10
标识
DOI:10.1177/09612033231187752
摘要

Studies of real-world effectiveness of belimumab in adults with systemic lupus erythematosus have shown improved disease control and decreased oral glucocorticoid use. However, belimumab use outside of clinical trial settings has not been well studied in childhood-onset systemic lupus erythematosus (cSLE). We aimed to characterize indications for belimumab use and evaluate oral glucocorticoid doses and disease activity scores in the year following belimumab initiation at a single, large pediatric rheumatology center.We included children and young adults with cSLE who received ≥ 1 dose of belimumab. Repeated measures one-way ANOVA was used to compare SLEDAI-2K scores and prednisone-equivalent daily oral glucocorticoid doses at baseline, 6 months, and 12 months after belimumab initiation for those who continued therapy for a year.We identified 21 patients with cSLE who received ≥ 1 dose of belimumab. The median disease duration at belimumab initiation was 30.8 months [IQR 21.0-79.1]. At the time of belimumab initiation, 100% of patients were taking an antimalarial, 81% were on oral glucocorticoids, and 91% were on at least one conventional DMARD. Thirteen patients (62%) continued belimumab for ≥6 months and 11 (52%) for ≥12 months. Among those continuing belimumab for ≥12 months, median [IQR] oral prednisone daily doses in milligrams at baseline, 6 months, and 12 months were 12.5 [7.5-17.5], 9 [6.25-10], and 5 [5-9.5], p = 0.037, and median [IQR] SLEDAI-2K scores at baseline, 6 months, and 12 months were 8 [5.5-10.5], 6 [3.5-10], and 6 [6-8.5], p = 0.548, respectively.In our cohort of pediatric patients with lupus and moderate disease activity treated with belimumab for ≥12 months, daily oral glucocorticoid doses were significantly lower 6 and 12 months after belimumab initiation than baseline. Use in patients with active nephritis was uncommon. Further research is needed in a large, multicenter cohort to determine the real-world effectiveness of belimumab in children and develop guidelines for use.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
醉熏的荣轩完成签到 ,获得积分10
刚刚
1秒前
2秒前
2秒前
2秒前
烟花应助你晖哥采纳,获得10
3秒前
1015508201完成签到,获得积分10
3秒前
3秒前
Akim应助哈哈哈哈采纳,获得10
3秒前
WC发布了新的文献求助10
4秒前
4秒前
美满花生发布了新的文献求助10
4秒前
英姑应助细心的文轩采纳,获得10
4秒前
5秒前
5秒前
cyw发布了新的文献求助10
5秒前
hullu完成签到,获得积分10
5秒前
5秒前
握手完成签到,获得积分20
5秒前
共享精神应助Epossible采纳,获得10
6秒前
shi发布了新的文献求助10
6秒前
lan发布了新的文献求助10
6秒前
6秒前
6秒前
6秒前
7秒前
杨祥朋发布了新的文献求助10
8秒前
8秒前
9秒前
LucienS发布了新的文献求助10
10秒前
淡定翠桃发布了新的文献求助50
10秒前
10秒前
兔兔sci完成签到,获得积分10
10秒前
kk发布了新的文献求助10
10秒前
七七发布了新的文献求助10
11秒前
ShanTay完成签到,获得积分10
12秒前
12秒前
传奇3应助昏睡的妙梦采纳,获得10
13秒前
Orange应助昏睡的妙梦采纳,获得10
13秒前
13秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974943
求助须知:如何正确求助?哪些是违规求助? 3519467
关于积分的说明 11198482
捐赠科研通 3255728
什么是DOI,文献DOI怎么找? 1797904
邀请新用户注册赠送积分活动 877261
科研通“疑难数据库(出版商)”最低求助积分说明 806224